U.S. President Donald Trump announced Thursday, November 6, an agreement with pharmaceutical companies to reduce the price of weight loss drugs, such as Ozempic and Wegovy, and increase coverage of these products in the Medicare and Medicaid health programs.
The pact, reached with pharmaceutical companies Eli Lilly and Novo Nordisk, seeks to make more accessible these drugs, which have become popular in recent years among people seeking to lose weight, but which, in the case of Ozempic, are also used to treat type 2 diabetes, among other diseases.
Trump lowers Ozempic price
🇺🇸 President Trump announces another HISTORIC PRICE SLASH on top drugs that help Americans struggling with diabetes, heart disease, obesity, and more.
💉Ozempic: $1,000 → $350/mo via TrumpRx
💉Wegovy: $1,350 → $350/moMAKE AMERICA HEALTHY AGAIN! pic.twitter.com/9lezvtZ6q0
– The White House (@WhiteHouse) November 6, 2025
“This is very exciting because, once again, we are reducing drug prices to levels that no one thought possible,” Trump celebrated in the Oval Office accompanied by Health Secretary Robert Kennedy Jr. and pharmaceutical executives.
As he explained, the two pharmaceutical companies committed to offer Wegovy and Zepbound, also for weight control, at “Most Favored Nation rates”, referring to WTO rules.
Ozempic and Wegovy prices will drop from $1,000 and $1,350 per month, respectively, to $350 if purchased through TrumpRx, the current U.S. government’s new initiative to sell drugs from some pharmaceuticals at a reduced price by employing the most favored nation mechanism.
In addition, a price of $150 was agreed upon for the initial dose of the oral version of GLP-1 drugs, named after a key intestinal hormone in the regulation of sugar and appetite, which are still in the testing phase.
This reduction, according to the agreement’s explanatory shared by the White House, will allow “Medicare and Medicaid to cover anti-obesity drugs for adults at a drastically lower cost to taxpayers.”
Beneficiaries of Medicare, the federal health program for those 65 and older, will be able to get these drugs with a co-payment of $50 per month.
“It’s a win for American patients that will save lives and improve the health of millions of Americans,” Trump said in the Oval Office as he announced the pact.
The pact, reached with pharmaceutical companies Eli Lilly and Novo Nordisk, seeks to make more accessible these drugs, which have become popular in recent years among people seeking to lose weight, but which, in the case of Ozempic, are also used to treat type 2 diabetes, among other diseases.
Salvará vidas y mejorará la salud de millones de estadounidenses
Donald Trump
With information from EFE
